Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387572 | 0.85 | VCAM1 (0.55) | VCAM1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL5861079 | 0.85 | VCAM1 (0.55) | VCAM1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL18657403 | 0.85 | PDE7A (0.60) | VCAM1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL2080483 | 0.81 | VCAM1 (0.51) | VCAM1TDP1PDE7AMAPK1 | |
| SCHEMBL21573611 | 0.81 | VCAM1 (0.54) | VCAM1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL27957717 | 0.80 | VCAM1 (0.50) | VCAM1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL23507204 | 0.79 | PDE7A (0.58) | VCAM1TDP1PDE7ATSHRMAPK1 | |
| SCHEMBL24254563 | 0.77 | VCAM1 (0.54) | VCAM1TDP1 | |
| SCHEMBL11574501 | 0.77 | PDE7A (0.56) | VCAM1TDP1PDE7A | |
| SCHEMBL9182158 | 0.77 | VCAM1 (0.47) | VCAM1TDP1PDE7ATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989263-B1 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-24 | — | — | US | claimed |
| US-6943268-B2 | Method for induction of L-selectin shedding | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2005-09-13 | — | — | US | disclosed |
| US-20030092763-A1 | Method for induction of L-selectin shedding | SCIENCE & TECHNOLOGY CORPORATION @UNM | 2003-05-15 | — | — | US | disclosed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6498189-B1 | SUPPRESSION OF INFLAMMATION AND OF LYMPH NODE ENTRY BY CALMODULIN ANTAGONISTS; CELL ASSOCIATED PROTEIN DISULFIDE ISOMERASE INHIBITORS; P-AMINOPHENYLARSINE OXIDES | UNIVERSITY OF NEW MEXICO | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092763-A1 | Method for induction of L-selectin shedding | PDIA5, PDIA4, PDIA6 | VCAM1 14/4885TDP1 3141/4885PDE7A 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.